Drug Trial Radar · NCT07474558
SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
102
Planned (sponsor's estimate)
Start
Oct 23, 2026
Primary completion
Jan 15, 2030
Study completion Sep 15, 2031
Sponsor
- Lead sponsor
- Jules Bordet InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- BelleTorus Corporation; Gilead Sciences; Paxman
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this interventional study is to determine if scalp cooling (by the Paxman Scalp Cooling System) reduces the extent and severity of alopecia in participants with advanced solid tumours receiving ADC. The main question it aims to evaluate the efficacy of scalp cooling in reducing chemotherapy-induced alopecia in participants with advanced/metastatic solid tumours receiving antibody-drug conjugates (trastuzumab-deruxtecan, sacituzumab-govitecan, or datopotamab-deruxtecan), as assessed by blinded central dermatological review. Researchers will compare the experimental arm (ADC treatment + scalp cooling) with the control arm (ADC only). Scalp cooling will be done each day of ADC treatment : before, during and post-infusions of their ADC treatment.
Conditions
- Advanced or Metastatic Solid Tumour
- Antibody-Drug Conjugate
- Alopecia
Interventions
scalp coolingDevice
scalp cooling at -10°C for each cycle of ADC, subjects will ubdergo scalp cooling : 30 minutes prior ADC treatment, during ADC treatment and 90 minutes following ADC treatment
photographs via the Belle.AI appOther
artificial intelligence-based software tool designed for standardised photographic documentation and automated assessment of alopecia severity using the Severity of Alopecia Tool (SALT) scale generated AI Score will be blinded for investigator and patient outcome does not impact treatment of the subject
Antibody-Drug ConjugatesDrug
study will randomize female participants receiving one of the following ADCs as part of their standard-of-care treatment: sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- percentage of participants with hair lossTime frame: 3 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CHU Helora - Hopital de Mons - Site Kennedy
Mons, Belgium · Not yet recruiting
CHU UCL Namur Site Sainte Elisabeth
Namur, Belgium · Recruiting
Institut Jules Bordet
Anderlecht, Brussels Capital, Belgium · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.